JP7761371B2 - 対象におけるマイトファジーを改善するための方法 - Google Patents

対象におけるマイトファジーを改善するための方法

Info

Publication number
JP7761371B2
JP7761371B2 JP2019548663A JP2019548663A JP7761371B2 JP 7761371 B2 JP7761371 B2 JP 7761371B2 JP 2019548663 A JP2019548663 A JP 2019548663A JP 2019548663 A JP2019548663 A JP 2019548663A JP 7761371 B2 JP7761371 B2 JP 7761371B2
Authority
JP
Japan
Prior art keywords
urolithin
muscle
compound
salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514338A (ja
JP2020514338A5 (https=
Inventor
リンシュ，クリストファー
アンドリュー，ペネロペ
シング，アヌラーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazentis SA
Original Assignee
Amazentis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1703735.9A external-priority patent/GB201703735D0/en
Priority claimed from GBGB1706594.7A external-priority patent/GB201706594D0/en
Priority claimed from GBGB1707861.9A external-priority patent/GB201707861D0/en
Application filed by Amazentis SA filed Critical Amazentis SA
Publication of JP2020514338A publication Critical patent/JP2020514338A/ja
Publication of JP2020514338A5 publication Critical patent/JP2020514338A5/ja
Priority to JP2023076848A priority Critical patent/JP2023100869A/ja
Application granted granted Critical
Publication of JP7761371B2 publication Critical patent/JP7761371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
JP2019548663A 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法 Active JP7761371B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076848A JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1703735.9 2017-03-08
GBGB1703735.9A GB201703735D0 (en) 2017-03-08 2017-03-08 Methods for improving mitophagy in subjects
GBGB1706594.7A GB201706594D0 (en) 2017-04-25 2017-04-25 Methods for improving mitophagy in subjects
GB1706594.7 2017-04-25
GBGB1707861.9A GB201707861D0 (en) 2017-05-16 2017-05-16 Methods for improving mitophagy in subjects
GB1707861.9 2017-05-16
PCT/EP2018/055788 WO2018162650A1 (en) 2017-03-08 2018-03-08 Methods for improving mitophagy in subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076848A Division JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Publications (3)

Publication Number Publication Date
JP2020514338A JP2020514338A (ja) 2020-05-21
JP2020514338A5 JP2020514338A5 (https=) 2021-04-22
JP7761371B2 true JP7761371B2 (ja) 2025-10-28

Family

ID=61691936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548663A Active JP7761371B2 (ja) 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法
JP2023076848A Pending JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076848A Pending JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Country Status (4)

Country Link
US (1) US20180256538A1 (https=)
EP (2) EP4553071A3 (https=)
JP (2) JP7761371B2 (https=)
WO (1) WO2018162650A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
JP7761372B2 (ja) * 2017-03-08 2025-10-28 アマゼンティス エスアー 対象におけるマイトファジーを改善するための方法
US20230041432A1 (en) * 2019-03-21 2023-02-09 Fonterra Co-Operative Group Limited Compositions comprising polar lipids for maintaining or increasing mobility and vitality
CA3150587A1 (en) * 2019-09-25 2021-04-01 Societe Des Produits Nestle S.A. Compositions and methods using adenosylcobalamin
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
EP4065102A1 (en) * 2019-11-27 2022-10-05 Société des Produits Nestlé S.A. Benzocoumarin ampk activator compounds, compositions, methods and uses thereof
JP2023503276A (ja) * 2019-11-27 2023-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ａｍｐｋ間接活性化化合物と組み合わせたａｍｐｋ直接活性化化合物、組成物、方法、及びそれらの使用
CA3206062A1 (en) * 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
US20240307320A1 (en) * 2021-07-08 2024-09-19 Biophagy, Inc. A System and Method for Measuring and Stimulating Autophagy
KR102677423B1 (ko) * 2021-09-17 2024-06-21 조선대학교산학협력단 망기페린을 포함하는 자가포식 활성화용 조성물
EP4452259A1 (en) * 2021-12-20 2024-10-30 Société des Produits Nestlé S.A. Compositions comprising urolithin for treating muscle decline and a kidney dysfunction
JP2025510123A (ja) 2022-03-22 2025-04-14 アマゼンティス エスアー 組成物
CN115607671A (zh) * 2022-10-26 2023-01-17 深圳大学 一种提高运动皮层尿石素a浓度的方法及应用
EP4712958A2 (en) * 2023-05-18 2026-03-25 Vandria SA Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosis
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
JP2015523362A (ja) 2012-06-27 2015-08-13 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073612A2 (en) * 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
WO2009137859A1 (en) * 2008-05-15 2009-11-19 Alois Jungbauer Compounds for the treatment of metabolic syndrome and insulin resistance
GB201323008D0 (en) * 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP7761372B2 (ja) * 2017-03-08 2025-10-28 アマゼンティス エスアー 対象におけるマイトファジーを改善するための方法
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
JP2015523362A (ja) 2012-06-27 2015-08-13 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nature Medicine, 2016, 発行日, Vol.22, No.8, p.879-888
Neurochemistry International, 2017年02月21日, 発行日, Vol.109, p.202-209

Also Published As

Publication number Publication date
EP4553071A2 (en) 2025-05-14
JP2020514338A (ja) 2020-05-21
JP2023100869A (ja) 2023-07-19
EP4553071A3 (en) 2025-07-23
EP3592424A1 (en) 2020-01-15
WO2018162650A1 (en) 2018-09-13
US20180256538A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
JP7761371B2 (ja) 対象におけるマイトファジーを改善するための方法
JP7761372B2 (ja) 対象におけるマイトファジーを改善するための方法
US20240148690A1 (en) Compositions comprising urolithin compounds
AU2016202656B2 (en) Combination of components for the prevention and treatment of frailty
US11123407B2 (en) Nutritional composition for treating or preventing impaired mobility
JP6368306B2 (ja) 炎症性腸疾患（ｉｂｄ）患者の筋骨格の健康を促進させるための栄養組成物
JP2016507500A (ja) Ｇｉ管障害を治療するための方法
HK40127507A (en) Methods for improving mitophagy in subjects
HK40127528A (en) Methods for improving mitophagy in subjects
JP2025530777A (ja) Ｄ１０－ドコサヘキサエン酸又はそのエステルの医薬組成物
KR20250133322A (ko) 우롤리틴과 케톤체의 조합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230626

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251016

R150 Certificate of patent or registration of utility model

Ref document number: 7761371

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150